Noxopharm has announced promising new data in support of a future human trial for SOF-SKN™, the company’s cutaneous lupus drug candidate, confirming several important characteristics of the drug and representing a positive step in its refinement.
Read more here: www.noxopharm.com/pdf/a094654d...
